This item demonstrates the stranglehold that Big Pharma has on Universities and medical schools.
https://medium.com/@gregggonsalves/statement-from-yale-faculty-on-hydroxychloroquine-and-its-use-in-covid-19-47d0dee7b2b0"Statement from Yale Faculty on Hydroxychloroquine and its Use in COVID-19Statement from Yale Faculty on Hydroxychloroquine and its Use in COVID-19
Gregg Gonsalves
Aug 4, 2020
We write with grave concern that too many are being distracted by the ardent advocacy of our Yale colleague, Dr. Harvey Risch, to promote the assertion that hydroxychloroquine (HCQ) when given with antibiotics is effective in treating COVID-19, in particular as an early therapeutic intervention for the disease. As his colleagues, we defend the right of Dr. Risch, a respected cancer epidemiologist, to voice his opinions. But he is not an expert in infectious disease epidemiology and he has not been swayed by the body of scientific evidence from rigorously conducted clinical trials, which refute the plausibility of his belief and arguments. Over the last few weeks, all of us have spent considerable time explaining the evidence behind HCQ research, as it applies to early and late stage COVID-19 patients to the scientific community and general public, and now are compelled to detail the evidence in this open letter.
We are seriously alarmed for the safety of patients and the coherence and effectiveness of our national COVID-19 emergency response when misinformation about HCQ is spread and when rigorous scientific evidence and consensus produced by the community of expert researchers in infectious diseases, federal agencies and national and global health organizations are not heeded. Let us be clear: we are unanimous in our desire to see the development of therapies to treat COVID-19 and to prevent the transmission or acquisition of SARS-CoV-2. If HCQ was shown to be effective, even among subgroups of patients with COVID-19 in ongoing high quality trials, we would join our colleagues in promoting access to it for all who need it. However, the evidence thus far has been unambiguous in refuting the premise that HCQ is a potentially effective early therapy for COVID-19.
At this point in time Big Pharma's legacy media and their financed lackeys in academia, were still riding the wave of the fraudulent VA trial and the fake "study" published in and subsequently withdrawn from The Lancet that used fictitious data. While the Lancet study was withdrawn within a couple weeks of publication, the media and judging from this hit piece apparently academia as well, were still trying to ride that fraudulent wave.
VA “Study” on Hydroxychloroquine Challenged, Gilead’s Drug Remdesivir IneffectiveEXCLUSIVE: The Lancet Study on Hydroxychloroquine Was a COMPLETE FRAUD HCQ is used for the treatment of rheumatological diseases, such as lupus and rheumatoid arthritis. However, this does not ensure that the drug will be safe in patients with COVID-19 or in widespread use to treat early illness. In fact, rigorously-conducted clinical trials have found that HCQ is not effective as an early prophylactic therapy in preventing illness due to COVID-19 in people exposed to the virus. Furthermore, HCQ, alone or together with the antibiotic, azithromycin, has not been shown to be effective in improving the clinical status of patients with COVID-19. Moreover, clinical trials have found that treatment with HCQ may be associated with increased risk of adverse reactions. Taken together, the scientific evidence does not support the widespread use of this drug, alone or in combination with an antibiotic, as advocated by Dr. Risch and others, unless rigorous evidence from clinical trials demonstrates otherwise.
Notice that they do not make a reference to zinc here or in any of the rest of their lying defamation of Dr. Harvey Risch, because that's perhaps the most essential part of the triple therapy, that was dubbed The Zelenko Protocol. HCQ is an ionophore that helps move the zinc into the cells so it can preclude replication of the virus inside the cell. Zelenko described the zinc as is the bullet and hydroxychloroquine is the gun - the delivery mechanism. A gun and a bullet are useless by themselves.
By March 23, Zelenko had cured his first 500 elderly and high-risk patients and reported his results to the President of the U.S.
Dr. Zelenko recommendations of 3-23-2020 - 500 patients 0 deaths 0 hospitalizedBy the date these homicidal creeps published this defamation of Dr. Harvey Risch, thousands of doctors in the U.S. had been enjoying 99+% success in early treatment of hundreds of thousands of elderly and high-risk patients with HCQ+zinc+azithromycin.
Trials bear that out as well.
https://c19hcq.com/#earlyFinally, we point to the recent memorandum from the US Food and Drug Administration revoking the Emergency Use Authorization for HCQ that has assembled the data on the drug as of June 2020 (Food and Drug Administration Memorandum Explaining Basis for Revocation of Emergency Use Authorization for Emergency Use of Chloroquine Phosphate and Hydroxychloroquine Sulfate).
Which the FDA pulled EUA on the basis of the fraudulent study published in the Lancet, a while after the study had been discovered to be a fraud, and further used that fraudulent to suspend trials of HCQ.
FDA removed EUA for HCQ and gave to Remdesivir instead - neglegent homicide?So that Fauci could get EUA for his Big Pharma boy's comparatively grossly ineffective and dangerous patented Remdesivir.
WHO "STUDY: Remdesivir Does Not Reduce COVID Mortality" or shorten hospital stayOr on the basis of the homicidal over-dosing WHO and UK trials.
Covid-19 Has Turned Public Health Into a Lethal, Patient-Killing Experimental EndeavorWHO "Solidarity" and UK "Recovery" Clinical Trials of HCQ used Lethal Dosing?The Infectious Diseases Society of America now advises against the drug alone or in combination with azithromycin in the setting of COVID-19 except in the context of ongoing clinical studies. If these trials do show a clinical benefit for HCQ, we would revise our views on its use in the management of COVID-19.But who's going to fund a study of a generic drug that only costs a couple of bucks per course of treatment? That is, of course, besides of Big Pharma's surrogates who proceeded to set up trial after trial that were designed to fail - never using the triple therapy. But of the very few that did, they met with success in the 90 percentile.
The disproportionate focus on treatment with HCQ, in addition to the lack of a strong scientific rationale for its use and the risk of its potentially harmful effects, has major opportunity costs. In a recent analysis of COVID-19 clinical trials, one in every six studies of treatments against SARSCoV-2 was designed to study HCQ or chloroquine. We understand the desperation of many to see an effective treatment for COVID-19 emerge that will stop the pandemic in its tracks or slow its relentless spread in the US.
Meanwhile thousands of doctors had cured hundreds of thousands of patients with it in the U.S. with no significant side effects, while the Yale boys in their white lab coats decided it was better to sit idly by and be silent about early treatment, while Americans died by the hundreds of thousands by drowning in their own body fluids through Fauci's and the NIH "standard of care" and Remdesivir.
Fauci's "go home and isolate" treatment for COVID - a death sentence for someNIH deadly recommendations compared to those of COVID-competent professionalsBut investing our resources in HCQ after multiple studies have not shown it to be effective for COVID-19 has serious implications for more than just individual patients. The continuing advocacy on behalf of HCQ distracts us from advancing the science on COVID-19 and seeking more effective interventions in a time when more than 1000 people are dying per day of this disease.
No the lies of Big Pharma's water carriers like these boys are what killed hundreds of thousands of Americans,
There are multiple approaches to expedite the evaluation and approval of drugs for serious and life-threatening diseases in the US that have existed for decades now, but they all still rely on data from rigorous, well-conducted clinical trials to guide us. In addition, this ongoing promotion of HCQ has global implications as well, as many countries in the global South only have access to HCQ and use of HCQ is still common in this setting despite the lack of evidence and potential risks.
Simply compare the death rate in the U.S. with that in countries where HCQ is widely used to easily expose this lie:
https://www.bitchute.com/video/xR4druFBssHd/It is critical that we follow the science and where the evidence leads us on a quest to treat and prevent COVID-19.
And thousands of competent successful clinicians did exactly follow the science, as they continued to develop it through the scientific method, along with their colleagues. Not a bunch of nitwits opining from a lab.
In this climate, it’s important to rely on the data above all else when making clinical or regulatory decisions. Making these kinds of choices guided by personal endorsements outside of the context of the existing scientific evidence is medicine by testimonial and risks people’s lives.
So the best way to go about that is to defame a colleague who is well familiar with the wildly successful real world saving of lives through treatment with hydroxychloroquine.
Randomized controlled trials are how we keep from fooling ourselves, test our assumptions about new drugs and new uses for old ones.
That's the stupidity of academia. Randomized trials take months or longer, as hundreds of thousands of Americans are dying. Meanwhile ever since March, 99+% successful treating physicians continue to save Americans, through the art and science of evidence-based medicine.
For instance, flecainide was initially proposed as a drug to treat those at risk of severe arrhythmias after sudden myocardial infarction. However, the Cardiac Arrhythmia Suppression Trial showed for the first time that mortality was actually three times higher among persons receiving the drug for this purpose. Even though the drug was known to be effective in those experiencing severe arrhythmia, it ended up increasing mortality in those simply at risk. And no one noticed because sudden death after myocardial infarction was not a rare event and this tripling of the risk was not detected until a randomized, controlled trial was done.
So then it was time to break out the straw man.
The FDA has rescinded the EUA for HCQ for a reason: the vast preponderance of the evidence suggests that the drug is without merit in clinical care for COVID-19 and presents real dangers to patients by its continued use.
That reason being the fraudulent trial that used fictitious data that was withdrawn from the Lancet, as well as the WHO and UK trials that used lethal dosing in order to make HCQ appear to be dangerous, when it is widely known to be one of the safest drugs on the planet. Taken by millions of Americans every day of the year, decade after decade, for Lupus and rheumatoid arthritis, in the same dosage that the Zelenko protocol prescribes over just 7 days. But lies like those here succeeded in killing hundreds of thousands of Americans that could have gotten better in a few days with early treatment with the triple therapy.
Cutting EUA for 60 year proven safe HCQ in order to turn around and gave EUA to the
known dangerous experimental drug Remdesivir, that had even had to be pulled from prior trials for zika virus, because of the volume of patients it injured and killed.
In 1987, University of California at Berkeley Professor Peter Duesberg gained notoriety by expounding on his belief that AIDS was not caused by the human immunodeficiency virus, but by antiretroviral agents like azidothymidine (AZT) and recreational drugs. However, the data on antiretroviral therapy was clear: these drugs extended life and health and turned around the course of the AIDS epidemic worldwide. But Professor Duesberg persisted in his quest. Professor Duesberg’s thesis dissuaded many from taking antiretroviral therapy, and after the President of South Africa Thabo Mbeki endorsed these views, it led to delays in the roll-out of these life-saving drugs costing hundreds of thousands of lives in that country. While minority opinions, anecdotal evidence, novel interpretations and challenges to orthodoxies in a field can be important, at some point, the application of the scientific method generating evidence from multiple, well-designed clinical trials and observational studies does matter and should be heard over the noise of conspiracy theories, purported hoaxes, and the views of zealots.
So they close with yet another straw man argument, while hundreds of thousands of Americans were dying from doctor and hospital neglect and negligence. While competent clinicians had been healing patients with HCQ even with 100% success as early as March.
Signed,
Jason Abaluck, PhD
Associate Professor of Economics
Yale School of Management
Amy Bei, PhD
Assistant Professor of Epidemiology (Microbial Diseases)
Yale School of Public Health
Theodore Cohen, MD, DPH
Professor of Epidemiology (Microbial Diseases)
Co-director, Public Health Modeling Concentration
Yale School of Public Health
Gary V. Desir, MD
Paul B. Beeson Professor of Medicine
Vice Provost, Faculty Development and Diversity
Chair, Internal Medicine, Yale School of Medicine
Chief, Internal Medicine, Yale New Haven Hospital
Gail D’Onofrio MD
Professor & Chair, Emergency Medicine
Yale School of Medicine
Yale School of Public Health
Howard P. Forman, MD, MBA
Professor of Radiology & Public Health (Health Policy)
Yale School of Public Health
Yale School of Medicine
Professor in the Practice of Management
Yale School of Management
Alison Galvani, PhD
Burnett and Stender Families Professor of Epidemiology (Microbial Diseases)
Director of the Center for Infectious Disease Modeling and Analysis (CIDMA)
Yale School of Public Health
Gregg Gonsalves, PhD
Assistant Professor of Epidemiology (Microbial Diseases)
Yale School of Public Health
Associate Professor (Adjunct) and Research Scholar
Yale Law School
Nathan D. Grubaugh, PhD
Assistant Professor of Epidemiology (Microbial Diseases)
Yale School of Public Health
Roberta Hines, MD
Nicholas M. Greene Professor & Chair of Anesthesiology
Yale School of Medicine
Valerie Horsley, PhD
Associate Professor of Molecular, Cellular & Developmental Biology
Yale University
Akiko Iwasaki, PhD
Waldemar Von Zedtwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology
Yale School of Medicine
Professor of Molecular Cellular and Developmental Biology
Yale University
Amy Kapczynski, JD
Professor of Law
Yale Law School
Trace Kershaw, PhD
Department Chair and Susan Dwight Bliss Professor of Public Health (Social and Behavioral Sciences)
Yale School of Public Health
Albert I. Ko, MD
Professor of Epidemiology and Medicine and Chair of Epidemiology of Microbial Diseases
Yale School of Public Health
Stephen R. Latham, JD, PhD
Director, Interdisciplinary Center for Bioethics
Yale University
Brett Lindenbach, PhD
Associate Professor, Microbial Pathogenesis
Yale School of Medicine
Fiona Scott Morton, PhD
Theodore Nierenberg Professor of Economics
Yale School of Management
Ruslan Medzhitov, PhD
Sterling Professor of Immunobiology
Yale School of Medicine
Saad B. Omer, MBBS MPH PhD FIDSA
Professor of Medicine (Infectious Diseases),Yale School of Medicine
Adjunct Professor, Yale School of Nursing
Susan Dwight Bliss Professor of Epidemiology of Microbial Diseases, Yale School of Public Health
A. David Paltiel, PhD
Professor of Health Policy & Management
Yale School of Public Health
Yale School of Management
Sunil Parikh, MD, MPH
Associate Professor of Epidemiology and Medicine
Yale School of Public Health
Yale School of Medicine
Karen Santucci, MD
Professor & Chief, Pediatric Emergency Medicine
Yale School of Medicine
Marcella Nunez Smith, MD, MHS
Associate Professor, General Internal Medicine, Public Health, and Management
Yale School of Medicine
Yale School of Public Health
Yale School of Management
Director, Equity Research and Innovation Center
Daniel Weinberger, PhD
Associate Professor of Epidemiology (Microbial Diseases)
Yale School of Public Health
More from Gregg Gonsalves
Gregg Gonsalves is an Assistant Professor in the Department of the Epidemiology of Microbial Diseases at Yale School of Public Health.
Published in GEN
So are all those doctors just that stupid, or is there something else going on?big pharma funding for Yale University
https://duckduckgo.com/?q=big+pharma+funding+for+Yale+University&t=h_&ia=web"The total spent in Connecticut by 15 pharmaceutical companies was
$33,936,255, but most of that was paid directly to Yale or other institutions without a doctor named, or to doctors in relatively small amounts. Yale University or affiliated organizations received a total of $8.28 million from 2009 to 2012, according to the database. In Connecticut overall, more than 2,300 payments were made over four years by pharmaceutical companies, including multiple payments to the same doctor or institution."
https://www.middletownpress.com/lifestyle/article/Most-Big-Pharma-payments-in-Connecticut-for-Yale-11812686.php"Yale startup partners with big pharma
Yale biotech company Arvinas recently announced deals worth hundreds of millions of dollars with pharmaceutical companies Genentech and Pfizer. Yale biotech company Arvinas recently announced deals worth hundreds of millions of dollars with pharmaceutical companies Genentech and Pfizer."
https://yaledailynews.com/blog/2018/01/24/yale-startup-partners-with-big-pharma/https://yaledailynews.com/blog/2018/01/24/yale-startup-partners-with-big-pharma/Gee, no conflicts of interest there!
Nothing to see here folks, move along, move along......
Dr. Harvey Risch preferred to be honest rather than a "team player" whose ilk have the deaths of hundreds of thousands of Americans on their hands.
[edit add 7-11-23] Prestigious universities around the world accepted more than $60M from OxyContin family
https://www.usatoday.com/story/news/nation/2019/10/03/sackler-family-donations-imperial-college-london-university-sussex-yale/3849912002/https://duckduckgo.com/?q=yale+university+donations+from+Big+Pharma&va=v&t=ha&ia=webhttps://www.nhregister.com/health/article/Most-Big-Pharma-payments-in-Connecticut-for-Yale-11376006.php [end edit]
